Endocrine therapy of advanced carcinoma of the prostate.
Increasing evidence suggests that growth of the prostatic tissue is regulated by a network of hormones and growth factors, in which androgens play the prominent role. Hormonal manipulation remains the core of treatment for locally advanced and metastatic prostate cancer. Achievement of a complete androgen blockade, by surgical or medical means or a combination of both, offers superior results in palliative management of advanced disease. Management of hormonal refractory cancer, however, remains a challenge to clinicians.
Daneshgari
F
F
Division of Urology, University of Colorado Health Sciences Center, Denver 80262.
Crawford
E D
ED
D000315:Adrenalectomy; D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000502:physiology; D003131:Combined Modality Therapy; D004967:Estrogens / Q000502:physiology; D007987:Gonadotropin-Releasing Hormone / Q000502:physiology; D013006:Growth Hormone / Q000502:physiology; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D007016:Hypophysectomy; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011372:Progestins / Q000502:physiology; D011388:Prolactin / Q000502:physiology; D011467:Prostate / Q000254:growth & development; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*
D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D006133:Growth Substances; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone; D011388:Prolactin; D013006:Growth Hormone